Transaxial slices of baseline positron emission tomography (PET) and fused PET/magnetic resonance imaging (MRI; left) demonstrate a somatostatin receptor-expressing meningioma in the left cavernous ...
A simple blood draw can provide physicians with valuable information that can determine if peptide receptor radionuclide therapy (PRRT) is likely to be effective in a patient with neuroendocrine ...
Reston, VA—Peptide receptor radionuclide therapy (PRRT) is effective for clinical control of symptomatic metastatic insulinomas, according to new research published in the February issue of The ...
Combination of ZG005 with etoposide and cisplatin (EP) vs. EP as the first-line therapy for advanced neuroendocrine carcinoma: A randomized, multicenter, phase I/II trial. This is an ASCO Meeting ...
BARCELONA—In patients with inoperable progressive pancreatic cancer, a targeted radionuclide, lutetium-octreotate (OCLU), shows nearly double the 12-month progression-free survival (PFS) compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback